NASDAQ: ACETAdicet Bio Inc Stock
$1.02-0.04 (-3.77%)
Updated Dec 11, 2024
ACET Price
$1.02
Fair Value Price
$3.22
Market Cap
$84.05M
52 Week Low
$0.89
52 Week High
$3.77
P/E
-0.6x
P/B
0.4x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$117.88M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.16
Operating Cash Flow
-$92M
Beta
1.06
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ACET Overview
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ACET's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Value
C
Growth
D
Momentum
C
Sentiment
D
Safety
D
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ACET
Ranked#421 of 554
Ranked#421 of 554
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $19.53 | A | |
| $6.45 | A | |
| $120.72 | A |
Be the first to know about important ACET news, forecast changes, insider trades & much more!
ACET News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ACET scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACET ($1.02) is undervalued by 68.37% relative to our estimate of its Fair Value price of $3.22 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ACET ($1.02) is significantly undervalued by 68.37% relative to our estimate of its Fair Value price of $3.22 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ACET is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACET due diligence checks available for Premium users.
Valuation
ACET fair value
Fair Value of ACET stock based on Discounted Cash Flow (DCF)
Price
$1.02
Fair Value
$3.22
Undervalued by
68.37%
ACET ($1.02) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACET ($1.02) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACET is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACET price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.6x
Industry
-107.87x
Market
29.76x
ACET price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.4x
Industry
5.62x
ACET is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACET's financial health
Profit margin
Revenue
$0.0
Net Income
-$30.5M
Profit Margin
0%
ACET's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$246.0M
Liabilities
$34.4M
Debt to equity
0.16
ACET's short-term assets ($206.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACET's short-term assets ($206.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACET's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ACET's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.0M
Investing
-$96.6M
Financing
$0.0
ACET's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACET vs Biotech Stocks
Adicet Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.